Johannes Meiler
Overview
Explore the profile of Johannes Meiler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Welslau M, Potthoff K, Zaiss M, Muller L, Brucker C, Salat C, et al.
Oncol Res Treat
. 2024 Nov;
48(1-2):14-25.
PMID: 39551040
Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L...
2.
Grunwald V, Ivanyi P, Zschabitz S, Wirth M, Staib P, Schostak M, et al.
Eur Urol
. 2023 Sep;
84(6):571-578.
PMID: 37758574
Background: The role of immune checkpoint inhibitor (ICI) maintenance therapy in metastatic renal cell carcinoma (mRCC) is undefined. Objective: To determine whether switch maintenance therapy with nivolumab improves clinical outcomes...
3.
Kuemmel S, Heil J, Bruzas S, Breit E, Schindowski D, Harrach H, et al.
JAMA Surg
. 2023 Jun;
158(8):807-815.
PMID: 37285140
Importance: The increasing use of neoadjuvant systemic therapy (NST) has led to substantial pathological complete response rates in patients with initially node-positive, early breast cancer, thereby questioning the need for...
4.
Grunwald V, Hilser T, Meiler J, Goebell P, Ivanyi P, Strauss A, et al.
Oncol Res Treat
. 2022 Jan;
45(5):272-280.
PMID: 35045416
Introduction: Inhibition of neo-angiogenesis is a cornerstone of medical treatment in metastatic renal cell carcinoma (mRCC). While 1st line therapies were previously dominated by inhibitors of the vascular endothelial growth...
5.
Pape U, Kasper S, Meiler J, Sinn M, Vogel A, Muller L, et al.
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33121007
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients...
6.
Kasper S, Meiler J, Knipp H, Hohler T, Reimer P, Steinmetz T, et al.
Clin Colorectal Cancer
. 2020 Aug;
19(4):236-247.e6.
PMID: 32737003
Background: The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in KRAS (exon 2) wild-type (wt) metastatic...
7.
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al.
Lancet
. 2019 Apr;
393(10184):1948-1957.
PMID: 30982686
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and...
8.
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper S, Reis H, Ziegler S, Nothdurft S, Mueller A, Goetz M, et al.
Oncotarget
. 2017 May;
8(28):45898-45917.
PMID: 28507280
Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), cetuximab and panitumumab, are a mainstay of metastatic colorectal cancer (mCRC) treatment. However, a significant number of patients suffer from primary...
9.
Al-Batran S, Hofheinz R, Pauligk C, Kopp H, Haag G, Luley K, et al.
Lancet Oncol
. 2016 Oct;
17(12):1697-1708.
PMID: 27776843
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of resectable patients. Here we report findings from the...
10.
Wiesweg M, Eberhardt W, Reis H, Ting S, Savvidou N, Skiba C, et al.
J Thorac Oncol
. 2016 Aug;
12(1):54-64.
PMID: 27575422
Objectives: Chromosomal rearrangements involving ROS1 define a rare entity of lung adenocarcinomas with exquisite sensitivity to molecularly targeted therapy. We report clinical outcomes and genomic findings of patients with ROS1-positive...